Pharmaceutical salts of piroxicam and meloxicam with organic counterions

Huang, Shan; Venables, Dean S.; Lawrence, Simon E.

Pharmaceutical salts of piroxicam and meloxicam with organic counterions

dc.contributor.author	Huang, Shan
dc.contributor.author	Venables, Dean S.
dc.contributor.author	Lawrence, Simon E.
dc.contributor.funder	Science Foundation Ireland	en
dc.date.accessioned	2023-01-25T10:08:44Z
dc.date.available	2023-01-25T10:08:44Z
dc.date.issued	2022-10-21
dc.date.updated	2023-01-25T09:58:27Z
dc.description.abstract	Piroxicam (PRM) and meloxicam (MEL) are two nonsteroidal anti-inflammatory drugs, belonging to the Biopharmaceutics Classification System Class II drugs. In this study, six novel pharmaceutical salts of PRM and MEL with three basic organic counterions, that is, 4-aminopyridine (4AP), 4-dimethylaminopyridine (4DMP), and piperazine (PPZ), were prepared by both slurrying and slow evaporation. These salts were characterized by single-crystal and powder X-ray diffraction, thermal analysis, and Fourier transform infrared spectroscopy. All six salts, especially MEL-4DMP and MEL-4AP, showed a significantly improved apparent solubility and dissolution rate in sodium phosphate solution compared with the pure APIs. Notably, PRM-4AP and PRM-4DMP salts exhibited enhanced fluorescence, and the PRMPPZ salt showed weaker fluorescence compared with that of pure PRM due to different luminescence mechanisms.	en
dc.description.sponsorship	Science Foundation Ireland (12/RC/2275_P2)	en
dc.description.status	Peer reviewed	en
dc.description.version	Accepted Version	en
dc.format.mimetype	application/pdf	en
dc.identifier.citation	Huang, S., Venables, D. S. and Lawrence, S. E. (2022) 'Pharmaceutical salts of piroxicam and meloxicam with organic counterions', Crystal Growth and Design, 22(11), pp. 6504-6520. doi: 10.1021/acs.cgd.2c00722	en
dc.identifier.doi	10.1021/acs.cgd.2c00722	en
dc.identifier.eissn	1528-7505
dc.identifier.endpage	6520	en
dc.identifier.issn	1528-7483
dc.identifier.issued	11	en
dc.identifier.journaltitle	Crystal Growth and Design	en
dc.identifier.startpage	6504	en
dc.identifier.uri	https://hdl.handle.net/10468/14122
dc.identifier.volume	22	en
dc.language.iso	en	en
dc.publisher	ACS Publications	en
dc.relation.project	12/RC/2275_P2	en
dc.rights	© 2022, American Chemical Society. This document is the Accepted Manuscript version of a Published Work that appeared in final form Crystal Growth and Design, 22(11), pp. 6504-6520, after technical editing by the publisher. To access the final edited and published work see: https://doi.org/ 10.1021/acs.cgd.2c00722	en
dc.subject	Aggregation-induced emission	en
dc.subject	Co-crystals	en
dc.subject	Solid-state	en
dc.subject	Quantitative analysis	en
dc.subject	Structural analysis	en
dc.subject	Chemical stability	en
dc.subject	Melt extrusion	en
dc.subject	Hydrogen bond	en
dc.subject	Solubility	en
dc.subject	Cocrystals	en
dc.title	Pharmaceutical salts of piroxicam and meloxicam with organic counterions	en
dc.type	Article (peer-reviewed)	en